Chinese Journal of Antituberculosis ›› 2018, Vol. 40 ›› Issue (2): 161-167.doi: 10.3969/j.issn.1000-6621.2018.02.010
• Original Articles • Previous Articles Next Articles
Gui-qing HE,Feng SUN,Fei-fei SU,Ji-chan SHI,Hai-yan ZHU,Jian-yi DAI,Shou-feng YANG,Hong-ye NING,Xiao-ya CUI,Qun-hua LI,Xian-gao JIANG(),Wen-hong. ZHANG
Received:
2018-01-16
Online:
2018-02-10
Published:
2018-03-14
Contact:
Gui-qing HE
E-mail:xiangao368@163.com
Gui-qing HE,Feng SUN,Fei-fei SU,Ji-chan SHI,Hai-yan ZHU,Jian-yi DAI,Shou-feng YANG,Hong-ye NING,Xiao-ya CUI,Qun-hua LI,Xian-gao JIANG,Wen-hong. ZHANG. Treatment outcomes of the standardized regimens for patients with multildrug-resistant pulmonary tuberculosis in Wenzhou during 2013 to 2015[J]. Chinese Journal of Antituberculosis, 2018, 40(2): 161-167. doi: 10.3969/j.issn.1000-6621.2018.02.010
Add to citation manager EndNote|Ris|BibTeX
URL: http://www.zgflzz.cn/EN/10.3969/j.issn.1000-6621.2018.02.010
临床特征 | 例数 | 构成比或比率(%) |
---|---|---|
年龄(岁) | ||
<30 | 21 | 18.1 |
30~ | 80 | 69.0 |
>60 | 15 | 12.9 |
性别 | ||
男 | 83 | 71.6 |
女 | 33 | 28.4 |
肺部空洞 | 89 | 76.7 |
入组时临床症状 | ||
咳嗽 | 113 | 97.4 |
咯血 | 34 | 29.3 |
发热 | 22 | 19.0 |
乏力 | 30 | 25.9 |
胸痛 | 4 | 3.4 |
呼吸困难 | 11 | 9.5 |
并发糖尿病 | 32 | 27.6 |
HIV抗体 | ||
阳性 | 0 | 0.0 |
阴性 | 108 | 93.1 |
不详 | 8 | 6.9 |
既往治疗史 | ||
初治 | 39 | 33.6 |
复治 | 77 | 66.4 |
基线菌株耐药分类 | ||
单纯MDR-TB | 31 | 26.7 |
pre-XDR-TB | 47 | 40.5 |
XDR-TB | 13 | 11.2 |
不详 | 25 | 21.6 |
失访发生时间(33例) | ||
注射期 | 13 | 39.4 |
非注射期 | 20 | 60.6 |
治疗转归 | 单纯MDR-TBa (31例) | pre-XDR-TBb (47例) | XDR-TBc (13例) | χ2值 | P①值 | χ2值 | P②值 |
---|---|---|---|---|---|---|---|
治愈 | 21(67.7) | 15(31.9) | 2(15.4) | 9.648 | 0.002 | 10.064 | 0.002 |
完成治疗 | 0(0.0) | 5(10.6) | 0(0.0) | - | 0.151 | - | - |
治疗成功(治愈+完成治疗) | 21(67.7) | 20(42.6) | 2(15.4) | 4.753 | 0.029 | 10.064 | 0.002 |
治疗失败 | 2(6.5) | 10(21.3) | 7(53.8) | 4.914 | 0.027 | 12.645 | 0.000 |
死亡 | 0(0.0) | 4(8.5) | 1(7.7) | - | 0.147 | - | 0.295 |
失访 | 8(25.8) | 13(27.7) | 3(23.1) | 0.033 | 0.857 | 0.036 | 0.849 |
[1] | World Health Organization . Global tuberculosis report 2017. Geneva: World Health Organization, 2017. |
[2] |
Zhao Y, Xu S, Wang L , et al. National survey of drug-resistant tuberculosis in China. N Engl J Med, 2012,366(23):2161-2170.
doi: 10.1056/NEJMoa1108789 URL |
[3] |
Falzon D, Jaramillo E, Schünemann HJ , et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J, 2011,38(3):516-528.
doi: 10.1183/09031936.00073611 URL pmid: 21828024 |
[4] |
Falzon D, Schünemann HJ, Harausz E , et al. World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. Eur Respir J,2017,49(3):pii: 1602308.
doi: 10.1183/13993003.02308-2016 URL pmid: 5399349 |
[5] |
Zhang L, Meng Q, Chen S , et al. Treatment outcomes of multidrug-resistant tuberculosis patients in Zhejiang,China,2009—2013. Clin Microbiol Infect,2017, pii: S1198- 743X(17) 30363-4.
doi: 10.1016/j.cmi.2017.07.008 URL pmid: 28712668 |
[6] | 浙江省疾病预防控制中心. 浙江省耐多药肺结核防治工作指南. 杭州:浙江省疾病预防控制中心, 2014. |
[7] |
Turenne CY, Tschetter L, Wolfe J , et al. Necessity of quality-controlled 16S rRNA gene sequence databases: identifying nontuberculous Mycobacterium species. J Clin Microbiol, 2001,39(10):3637-3648.
doi: 10.1128/JCM.39.10.3638-3648.2001 URL |
[8] | Ringuet H, Akoua-Koffi C, Honore S , et al. hsp65 sequencing for identification of rapidly growing mycobacteria. J Clin Microbiol, 1999,37(3):852-857. |
[9] |
Barrera L, Cooreman E, de Dieu Iragena J , et al. Policy gui-dance on drug-susceptibility testing (DST) of second-line antituberculosis drugs. Geneva: World Health Organization, 2008.
URL pmid: 26290924 |
[10] |
Alene KA, Yi H, Viney K , et al. Treatment outcomes of patients with multidrug-resistant and extensively drug resistant tuberculosis in Hunan Province, China. BMC Infect Dis, 2017,17(1):573.
doi: 10.1186/s12879-017-2662-8 URL |
[11] | World Health Organization . The global plan to stop TB 2011—2015: transforming the fight towards elimination of tuberculosis. Geneva: World Health Organization, 2010. |
[12] |
Liu CH, Li L, Chen Z , et al. Characteristics and treatment outcomes of patients with MDR and XDR tuberculosis in a TB referral hospital in Beijing: a 13-year experience. PLoS One, 2011,6(4):e19399.
doi: 10.1371/journal.pone.0019399 URL |
[13] |
吕德良, 杨应周, 谭卫国 , 等. 深圳市耐多药结核病治疗转归分析. 中国热带医学, 2016,16(7):649-652.
doi: 10.13604/j.cnki.46-1064/r.2016.07.06 URL |
[14] | 杜雨华, 苏汝钊, 周惠贤 , 等. 116例耐多药肺结核治疗转归情况影响因素分析. 中国防痨杂志, 2012,34(1):19-22. |
[15] |
He XC, Tao NN, Liu Y , et al. Epidemiological trends and outcomes of extensively drug-resistant tuberculosis in Shandong, China. BMC Infect Dis, 2017,17(1):555.
doi: 10.1186/s12879-017-2652-x URL |
[16] |
Farhat MR, Jacobson KR, Franke MF , et al. Fluoroquinolone resistance mutation detection is equivalent to culture-based drug sensitivity testing for predicting multidrug-resistant tuberculosis treatment outcome: A retrospective cohort study. Clin Infect Dis, 2017,65(8):1364-1370.
doi: 10.1093/cid/cix556 URL |
[17] |
Oliveira O, Gaio R, Villar M , et al. Predictors of treatment outcome in multidrug-resistant tuberculosis in Portugal. Eur Respir J, 2013,42(6):1747-1749.
doi: 10.1183/09031936.00197912 URL pmid: 23988773 |
[18] |
中国防痨协会. 耐药结核病化学治疗指南(2015). 中国防痨杂志, 2015,37(5):421-469.
doi: 10.3969/j.issn.1000-6621.2015.05.001 URL |
[19] |
World Health Organization . WHO treatment guidelines for drug-resistant tuberculosis, 2016 Update. Geneva: World Health Organization, 2016.
URL pmid: 27748093 |
[1] | LIU Xiao-li, LEI Li-mei, GUO Zhou-li, HUANG Yin, XU Jing, ZHAO Xia, WANG Yan, FU Li. Study on the relationship of stigma and social support of tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 1002-1008. |
[2] | Academic Working Committee of Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis . Expert consensus of clinical application of fixed-dose combination formulations [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 885-893. |
[3] | JIN Hong-jian. The construction of tuberculosis prevention and control service system at county level in China needs to be strengthened urgently —— Comments and suggestions of an old tuberculosis control and prevention worker [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 896-902. |
[4] | ZHANG Can-you, XIA Hui, CHENG Jun. Testing and reporting requirements for Class Ⅱ biosafety cabinet in tuberculosis laboratory [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 903-909. |
[5] | ZHOU Lin, LIU Er-yong, MENG Qing-lin, CHEN Ming-ting, ZHOU Xin-hua, GAO Wei-wei, LIN Ming-gui, XIE Ru-ming. Evaluation of the quality of pulmonary tuberculosis diagnosis after the implementation of the newly revised WS 288-2017 Diagnosis for pulmonary tuberculosis standards [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 910-915. |
[6] | LIU Er-yong, WANG Qian, ZHOU Lin, ZHANG Guo-qin, ZHANG Xiu-lei, MA Yong-cheng, YANG Shu-min, WANG Cui, MENG Qing-lin, CHEN Ming-ting, LIN Ming-gui, TU De-hua.. Analysis of diagnostic quality of pulmonary tuberculosis with negative etiology in some areas of China [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 916-920. |
[7] | MENG Qing-lin, LI Jin-lan, LIN Ding-wen, MA Yong-cheng, HOU Shuang-yi, LIU Nian-qiang, ZHOU Lin. Analysis of the awareness about knowledge on the updated TB diagnosis standard among the practitioners in TB control institutions [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 921-925. |
[8] | WANG Qian, ZHOU Lin, LIU Er-yong, ZHAO Yan-lin, LI Tao, CHEN Ming-ting, YANG Li-jia, WANG Jia.. A survey on the diagnostic ability of tuberculosis in the county-level medical institutions in China [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 926-930. |
[9] | LI Ting, HE Jin-ge, SU Qian, LI Jing, LI Yun-kui, GAO Wen-feng, GAO Yuan, YANG Wen. Value of tuberculin test in screening tuberculosis infection in HIV infected/AIDS patients in Butuo County, Sichuan Province [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 931-936. |
[10] | LI Yun-kui, HE Jin-ge, SU Qian, LI Ting, LI Jing, GAO Wen-feng, YANG Wen, MAO Guang-yu. Value of tuberculin test in screening tuberculosis infection in HIV infected/AIDS patients in Butuo County, Sichuan Province [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 937-941. |
[11] | SU Qian, XIA Yong, LU Jia, WANG Dan-xia, HE Jin-ge. Analysis on the epidemiological characteristics of pulmonary tuberculosis among children aged 0-14 in Sichuan Province from 2009 to 2018 [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 942-947. |
[12] | DENG Ya-li, ZHANG Tian-hua, LIU Wei-ping, ZHANG Hong-wei, MA Yu, LI Peng.. Temporal and spatial clustering analysis of pulmonary tuberculosis incidence in Shaanxi Province from 2014 to 2018 [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 948-955. |
[13] | DONG Xiao, ZHAO Zhen, LIU Nian-qiang, WANG Sen-lu, CUI Yan. Analysis of the finding characteristics of pulmonary tuberculosis in the elderly population in Xinjiang Uygur Autonomous Region during 2009—2017 [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 956-961. |
[14] | MA Ting-long, HAN Yi, CHENG Xu, LIU Zhi-dong. Clinical observation on treatment effectiveness of transdermal ultrasound-mediated drug delivery combined with oral anti-tuberculosis drug in patients with chest wall tuberculosis [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 968-972. |
[15] | NAN Hai, ZHANG Yun, YANG Xin-ting, DUAN Hong-fei. Meta-analysis on the diagnostic value of GeneXpert MTB/RIF for bone and joint tuberculosis [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 973-980. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||